Jason Zemansky

Peter Lawson

George Farmer

Jonathan Chang

Jiale Song

Justin Zelin

Li Wang Watsek

Xiaochuan Dai

Yue-Wen Zhu

Allen Horn

Bradley Canino

Charles Zhu

Dara Azar

David Dai

Ellen Horste

Eric Musonza

Erik Lavington

Ernesto Rodriguez-Dumont

Jeet Mukherjee

Li Watsek

Peter Green

Philip Nadeau

Roger Song

Salim Syed

Yen-Der Li

- Kura Oncology presented preclinical data for its next-generation Farnesyl Transferase Inhibitor (FTI), **Darlifarnib (KO-2806)**, highlighting its potential to address innate and adaptive resistance to multiple classes of targeted therapies, including PI3Kα inhibitors, KRAS inhibitors, and anti-angiogenic tyrosine kinase inhibitors.  **[1422143_2145906_1]** **[1422143_2145906_2]** **[1422143_2145906_6]** 
- The company is scheduled to present **first preliminary clinical results** from its FTI program at the upcoming ESMO presentation in **October**.  **[1422143_2145906_1]** **[1422143_2145906_6]** 
- These clinical presentations will include monotherapy dose escalation data for KO-2806 in RAS mutant tumors, combination data of KO-2806 with Cabozantinib in renal cell carcinoma, and Tipifarnib with Alpelisib in PIK3CA mutant head and neck squamous cell carcinoma.  **[1422143_2145906_7]** 
- Kura Oncology reported a **strong financial position** with **$630.7 million** in cash and cash equivalents as of its last quarterly update and anticipates **$375 million** in near-term milestone payments.  **[1422143_2145906_8]**

Kura Oncology Provides Update on Farnesyl Transferase Inhibitor Program and Upcoming Clinical Data

Kura Oncology (KURA)